[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100302515":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":21,"centralContacts":25,"locations":35,"responsibleParty":52,"collaborators":29,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":29,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":29,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":38,"whyStopped":29,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Weill Medical College of Cornell University","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Adenosine\u002F Verapamil Arm","Adenosine: 0.84 mg\u002Fkg IV (140 mcg\u002Fkg\u002Fminute IV for 6 minutes) Verapamil: 0.15 mg\u002Fkg IV\n\nAdenosine is known to terminate ventricular arrhythmias that are due to triggered activity (ref Lerman). To study the effects of adenosine on PVC, the investigators will administer Verapamil to slow down the heart initially and adenosine after catheters are introduced to patients who are being treated for symptomatic PVC and have consented to treatment with an invasive electrophysiology study and catheter ablation.",[12],"Drug: Adenosine",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Adenosine","Adenosine: 0.84 mg\u002Fkg (140 mcg\u002Fkg\u002Fminute IV for 6 minutes) Verapamil 0.15 mg\u002Fkg",[9],[20],"Verapamil 0.15 mg\u002Fkg",[22],{"name":23,"affiliation":5,"role":24},"James E Ip, M.D","PRINCIPAL_INVESTIGATOR",[26,31],{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},"CONTACT","212 746 2158",null,"jei9008@med.cornell.edu",{"name":32,"role":27,"phone":33,"phoneExt":29,"email":34},"Dolores T Reynolds, BSN","212 746 4617","dtr2001@med.cornell.edu",[36],{"facility":37,"status":38,"city":39,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Weill Cornell Medicine","RECRUITING","New York","10065","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-74.00597,40.71427,{"lat":47,"lon":46},[50,51],{"name":32,"role":27,"phone":33,"phoneExt":29,"email":34},{"name":23,"role":27,"phone":28,"phoneExt":29,"email":30},{"type":53,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100302515","phase-4-use-of-adenosine-to-determine-the-electrophysiological-mechanism-of-premature-ventricular-contractions-100302515",false,"NCT03218137","Use of Adenosine to Determine the Electrophysiological Mechanism of Premature Ventricular Contractions","Inclusion Criteria:\n\n* Diagnosis of premature ventricular contractions (PVCs)\n* Scheduled to undergo an electrophysiology study with the intention of performing cardiac ablation for the treatment of PVCs\n* Male or female between the ages of 18 and 70 years\n* Capable of giving informed consent\n\nExclusion Criteria:\n\n* Any structural heart disease\n* Coronary artery disease (≥ 70% stenosis)\n* Current treatment with anti-arrhythmic drugs\n* Pregnant\n* Asthma (if administering adenosine)",true,"ALL","18 Years","70 Years",{"count":65,"type":66},100,"ESTIMATED","INTERVENTIONAL",[69],"PHASE4","Unblinded, controlled, non-randomized, mechanistic study to determine whether physiological mechanisms underlying PVC are sensitive to adenosine. One hundred subjects undergoing clinically-indicated, standard-of-care cardiac electrophysiology study (EPS) procedure for PVCs will receive adenosine and\u002For verapamil to learn if their arrhythmias are inducible similarly to sustained ventricular tachycardia.",[72],"Premature Ventricular Contraction (PVC)",[74,75],"Subjects","diagnosed","2026-06-18",{"date":78,"type":79},"2026-06-23","ACTUAL",{"date":81,"type":79},"2017-02-13",{"date":83,"type":66},"2027-12-31",{"name":5,"class":6},1]